anti-KIR3DL2 CAR T cells

Anti-KIR3DL2 CAR T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target the killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 2 (KIR3DL2/CD158k). Developed by researchers at MD Anderson Cancer Center, this therapy utilizes a single-chain variable fragment (scFv) derived from a proprietary murine monoclonal antibody, coupled with CD28 costimulatory and CD3ζ signaling domains. KIR3DL2 is highly expressed in various T-cell malignancies, including Sézary syndrome, transformed mycosis fungoides, and aggressive subtypes of peripheral T-cell lymphoma (PTCL), while remaining largely absent from normal tissues, thereby minimizing the risk of on-target, off-tumor toxicity and fratricide. Preclinical studies have demonstrated robust cytotoxic activity and complete tumor regression in xenograft models.

Other names

KIR3DL2-directed CAR T cell therapyKIR-3DL2-directed CAR T cell therapyKIR 3DL2-directed CAR T cell therapyKIR3DL2-targeted CAR T cellsKIR-3DL2-targeted CAR T cellsKIR 3DL2-targeted CAR T cells